FILING ANALYSIS · THURSDAY, NOVEMBER 12
MACROGENICS INC MGNX — 8-K: Results of Operations and Financial Condition
neutral
The company reported financial results for Q3 2026, highlighted recent corporate progress, and provided updates on its pipeline, including the completion of Phase 1 dose escalation for MGC028 and interim results for MGC026 and lorigerlimab, but did not disclose any quantified surprises or significant changes to guidance.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →